Ignite Creation Date:
2025-12-24 @ 7:34 PM
Ignite Modification Date:
2026-03-05 @ 10:32 PM
Study NCT ID:
NCT03940703
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-12-12
First Post:
2019-05-06
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2)
Sponsor:
EMD Serono Research & Development Institute, Inc.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2019-09-19
Start Date Type:
ACTUAL
Primary Completion Date:
2023-05-11
Primary Completion Date Type:
ACTUAL
Completion Date:
2026-05-01
Completion Date Type:
ESTIMATED
First Submit Date:
2019-05-06
First Submit QC Date:
None
Study First Post Date:
2019-05-07
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2024-05-06
Results First Submit QC Date:
None
Results First Post Date:
2024-06-04
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-11-28
Last Update Post Date:
2025-12-12
Last Update Post Date Type:
ESTIMATED